RedHill Biopharma Ltd

RedHill Biopharma Ltd. a specialty biopharmaceutical company primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204 which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva) an SK2 selective inhibitor which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia in Phase 2 study to treat advanced unresectable cholangiocarcinoma and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107 which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104 which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv Israel.